Searching for a cure, Improving lives

DMD Carrier Leaflet

 

Action Duchenne, in collaboration with Sue Kenwrick, Principal Genetic Councellor, Addenbrooke’s Hospital, Cambridge, have produced a ground-breaking leaflet ‘Being a Carrier for Duchenne Muscular Dystrophy’.

This leaflet was distributed to all Neuromuscular Centres, Genetic Services and groups working with families affected by Duchenne muscular dystrophy.

The inspiration for this leaflet came from workshops for Duchenne carriers and other female relatives held by Action Duchenne, as well as sibling events and discussions arising from the ‘What about Us’ element of the Lottery funded Takin’ Charge. Takin’ Charge looks at issues in Transition for young people and their families, affected by Duchenne.

The format of the leaflet follows frequently asked questions that come up when carriers or relatives are given an opportunity to discuss the issues involved.

The project has been led by the Duchenne community, thank you to all contributors who have made this valuable resource possible.

Please click here to take a look at the leaflet online (please note the following amendments to the links below)

  • Muscular Dystrophy UK www.muscular-dystrophy.org
  • Genetic Alliance UK www.geneticalliance.org.uk

If you have further questions or comments please contact us info@actionduchenne.org

We received some patient info leaflets on being a Duchenne carrier last week – just wanted to let you know that the Genetic Counsellors in the department were very pleased with them and will make good use of them” – Nicole Gossan PhD, Pre-Registration Clinical Scientist (Genomics), Molecular Genetics Laboratory, Cheshire and Merseyside Regional Genetics, Liverpool Women’s Hospital

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Summit presents data from Phase 1 clinical programme of lead utrophin modulator, ezutromid

June 22nd, 2017

Summit Therapeutics has today announced the presentation of clinical data from two Phase 1 clinical trials

Tell me more

What Raxone being given approval through the EAMS scheme means for the Duchenne community

June 22nd, 2017

  Over a number of years we have worked closely with Santhera Pharmaceuticals and other

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne